Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases, which is approaching Phase II readiness and SDC-1802 for cancer (preclinical). Backed by positive Phase I data, SDC-1801 is undertaking advanced toxicology studies and capsule formulation optimisation in preparations for Phase II. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 63.5% economic interest), previously out licensed to Sierra Oncology.
Healthcare |
Comment
Healthcare |
Spotlight — flash
Healthcare |
Spotlight — flash
Healthcare |
Comment
John Reader
CSO
Stephen Parker
Chairman
Tim Mitchell
CEO